Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2016-A01544-47 | Other Identifier | ID-RCB number, ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| France Parkinson Association | OTHER |
Not provided
Not provided
Not provided
Not provided
Pilot study:
Prospective, clinical assessment of :
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PD patients | 30 PD patients in ON and OFF levodopa conditions | ||
| Healthy control subjects | 30 age matched healthy control subjects | ||
| Neurological control subjects | 10 patients with defined supra nuclear palsy |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change in the neural network between patients in OFF levodopa conditions and control subjects | Measure evaluated by functional MRI during the realisation of a cognitive task: symbol digit modality test | Between two evaluation visits, on average at 3 months (baseline- 3 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in the neural network between patients in OFF-drug conditions and healthy control subjects | Measure evaluated by functional MRI during the realisation of two motor tasks | Between two evaluation visits, on average at 3 months (baseline- 3 months) |
| Change in the neural network between patients in OFF-drug conditions and healthy control subjects |
Not provided
Inclusion Criteria:
Parkinson's Disease group :
Patients with Parkinson's Disease, who where included in the PRODYGI-1 cohort still meeting the MP criteria, Always followed in the service of neurology and pathology of the movement.
Pathological control group:
Healthy control group:
Exclusion Criteria:
For all groups:
Not provided
Not provided
Patients with Parkinson's disease (PD)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Caroline MOREAU, MD | University Hospital, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Roger Salengro, CHRU | Lille | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Measure evaluated by resting state functional MRI |
| Between two evaluation visits, on average at 3 months (baseline- 3 months) |
| Change in the neural network between OFF-drug condition and ON-drug condition in patients | Measure evaluated by functional MRI, during the realisation of one cognitive task and two motor tasks | Between two evaluation visits, on average at 3 months (baseline- 3 months) |
| Change in the neural network between patients in OFF-drug conditions and neurological control subjects (with supra nuclear palsy) | Measure evaluated by functional MRI, during the realisation of one cognitive task and two motor tasks | Between two evaluation visits, on average at 3 months (baseline- 3 months) |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |